Attovia Therapeutics has announced a $90 million Series C financing led by Deep Track Capital. The funding will support clinical studies for ATTO-1310 and ATTO-3712, as well as advance multiple earlier-stage projects.
Attovia Therapeutics has announced a $90 million Series C financing led by Deep Track Capital. The funding will support clinical studies for ATTO-1310 and ATTO-3712, as well as advance multiple earlier-stage projects.
04/15/25, 11:38 AM
Location
san carlosMoney raised
$90 million
Industry
therapeutics
biotechnology
Round Type
series c
Investors
Illumina Ventures, Marshall Wace, Eco R1 Capital, Cormorant Asset Management, Nextech Ventures, Goldman Sachs Alternatives, Ven Bio, Frazier Life Sciences, Mirae Asset Capital Life Science, Sanofi Ventures, Vida Ventures, Deep Track Capital
Attovia Therapeutics, a clinical-stage biopharma company, has completed a $90 million Series C financing round. Led by Deep Track Capital, the round included new investors such as Vida Ventures and Sanofi Ventures, along with existing investors. The proceeds will fund early-stage clinical studies for treatments targeting chronic pruritus and atopic dermatitis. This financing is a testament to the company's promising platform and its focus on developing innovative therapies for immune-mediated diseases.
Company Info
Location
san carlos, california, united states
Additional Info
Attovia is creating a pipeline of biotherapeutics for the treatment of immune-mediated diseases. We leverage ATTOBODY™, our proprietary biologics platform, to generate first-in-class and best-in-class bispecifics and multispecifics.